Summary
Recently distorted chromatic contour perception has been demonstrated in Parkinson's disease (PD). The aim of our study is to determine the clinical factors which influence chromatic contour perception in PD. Chromatic and achromatic contour perception, colour discrimination and clinical data were evaluated in 73 patients with PD. We used a computer-aided method to determine the chromatic fusion time (CFT) which indicates the acuity of monochromatic contour perception. Chromatic CFT was generally shortened in patients as compared to controls (p < 0.01), whereas achromatic CFT was not significantly different. Variance analysis revealed the ability of colour discrimination and the risk of visual hallucinations as statistically significant (p < 0.05) variables influencing contour perception of certain stimuli. In contrast, disease stage, disease duration and disease severity have no relevant effect on chromatic contour perception in Parkinson's disease. On the basis of those properties one may suggest that distorted chromatic contour perception is due to an impairment at a central stage of visual processing in PD and an imbalance of the serotonergic system. Whether CFT is a reliable method to predict the individual risk of hallucinosis in PD has to be evaluated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, rev. APA, Washington DC
Barbato L, Rinalduzzi S, Laurenti M, Ruggieri S, Accornero N (1994) Colour VEPs in Parkinson's disease. Electroencephalogr Clin Neurophysiol 92: 169–172
Beck AT, Ward CJ, Mendelsohn M, Mock H, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–574
Berger B, Trottier S, Verney C, Gaspar P, Alvarez C (1988) Regional and laminar distribution of the dopamine and serotonin innervation in the macaque cerebral cortex: a radioautographic study. J Comp Neurol 273: 99–119
Birkmayer W, Riederer P (1975) Responsibility of extrastriatal areas for the appearance of psychotic symptoms. J Neural Transm 35: 175–182
Bodis-Wollner I (1990) Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 13: 296–302
Büttner Th, Kuhn W, Klotz P, Steinberg R, Voss L, Bulgaru D, Przuntek H (1993) Disturbance of colour perception in Parkinson's disease. J Neural Transm [PD-Sect] 6: 11–15
Büttner Th, Kuhn W, Patzold T, Przuntek H (1994) L-Dopa improves colour vision in Parkinson's disease. J Neural Transm [PD-Sect] 7: 13–19
Büttner Th, Kuhn W, Müller Th, Patzold T, Heidbrink K, Przuntek H (1995a) Distorted colour discrimination in “de novo” Parkinsonian patients. Neurology 45: 386–387
Büttner Th, Kuhn W, Przuntek H (1995b) Distorted colour contour perception in de novo Parkinsonian patients. Eur Neurol 35: 226–229
Bulens C, Meerwaldt JD, van der Wildt GJ (1988) Effect of stimulus orientation on contrast sensitivity in Parkinson's disease. Neurology 38: 76–81
Calzetti S, Franchi A, Taratufolo G, Groppi E (1990) Simultaneous VEP and PERG investigations in early Parkinson's disease. J Neurol Neurosurg Psychiatry 53: 114–117
Dowling JE (1990) Functional and pharmacological organization of the retina: dopamine, interplexiform cells, and neuromodulation. In: Cohen B, Bodis-Wollner I (eds) Vision and the brain. The organization of the central visual system. Raven Press, New York, pp 1–18
Fahn S, Elton RC, UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. Macmillan Health Care Information, New York, pp 153–164
Farnsworth D (1943) The Farnsworth-Munsell 100 Hue and dichotomous test for color vision. J Opt Soc Am 33: 568–578
Fischer P, Danielczyk W, Simanyi M, Streifler MB (1990) Dopaminergic psychosis in advanced Parkinson's disease. Adv Neurol 53: 391–396
Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W (1995) Predominant affection of the blue cone pathway in Parkinson's disease. Brain 118: 771–778
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Klawans HL (1988) Psychiatric side effects during the treatment of Parkinson's disease. J Neural Transm 27: 117–122
Lieberman A, Neophytides A, Kupersmith M (1979) Treatment of Parkinson's disease with dopamine agonists: a review. Am J Med Sci 278: 65–76
Livingstone MS, Hubel DH (1984) Anatomy and physiology of a color system in the primate visual cortex. J Neurosci 4: 309–356
Lueck CJ, Zeki S, Friston KJ, Deiber MP, Cope P, Cunningham VJ, Lammertsma AA, Kennard C, Frackowiak RSJ (1989) The colour centre in the cerebral cortex of man. Nature 340: 386–388
Moskovitz C, Moses H, Klawans H (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135: 669–675
Pasik P, Molinor-Rode R, Pasik T (1990) Chemically specified systems in the dorsal alteral geniculate nucleus of mammals. In: Cohen B, Bodies-Wollner I (eds) Vision and the brain. The organization of the central visual system. Raven Press, New York, pp 43–84
Paulus WM, Hömberg V, Cunningham K, Haliday AM (1986) Colour and brightness coding in the central nervous system: theoretical aspects and visual evoked potentials to homogenous red and green stimuli. Proc R Soc Lond 227: 53–66
Perry EK, Marshall E, Thompson P, McKeith IG, Collerton D, Fairbaion AF, Ferrier IN, Irving D, Perry RH (1993) Monoaminergic activities in Lewy Body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm [P-D Sect] 6: 167–177
Phillipson OT, Kilpatrick IC, Jones MW (1987) Dopaminergic innervation of the primary visual cortex in the rat, and some correlations with human cortex. Brain Res Bull 18: 621–633
Pieri L, Keller HH, Burkard W, Da Prada L (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272: 278–279
Price MJ, Feldman RG, Adelberg D, Kayne H (1992) Abnormalities in colour vision and contrast sensitivity in Parkinson's disease. Neurology 42: 887–890
Reader TA, Quesney LF (1986) Dopamine in the visual cortex of the cat. Experientia 42: 1242–1244
Reader TA, Grondin L (1987) Distribution of catecholamines, serotonin, and their major metabolites in the rat cingulate, pyriform-entorhinal, somatosensory, and visual cortex: a biochemical survey using high-performance liquid chromatography. Neurochem Res 12: 1087–1097
Rizzo M, Smith V, Pogorny J, Damasio AR (1993) Color perception profiles in central achromatopsia. Neurology 43: 95–1001
Rondot R, de Recondo J, Coignet A, Ziegler M (1984) Mental disorders in Parkinson's disease after treatment with L-Dopa. Adv Neurol 4: 59–269
Ruddock KH (1993) Acquired deficiencies of human colour vision. In: Kennard C (ed) Bailliere's clinical neurology. Visual perceptual deficits. Bailliere Tindall, London, pp 287–338
van Bezold W (1876) The theory of colour. Prag, Boston
Verriest G, van Laethem J, Uvijls A (1982) A new assessment of the normal ranges of the Farnsworth-Munsell 100 Hue test scores. Am J Ophthalmol 93: 635–642
West LJ (1962) Hallucinations. Grune&Stratton, New York
Zeki S (1980) The representation of colours in the cerebral cortex. Nature 284: 412–418
Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E (1993) Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 341: 562–563
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Büttner, T., Kuhn, W., Müller, T. et al. Visual hallucinosis: The major clinical determinant of distorted chromatic contour perception in Parkinson's disease. J. Neural Transmission 103, 1195–1204 (1996). https://doi.org/10.1007/BF01271204
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01271204